Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R.
Berry-Kravis E, et al.
J Child Adolesc Psychopharmacol. 2006 Oct;16(5):525-40. doi: 10.1089/cap.2006.16.525.
J Child Adolesc Psychopharmacol. 2006.
PMID: 17069542
Clinical Trial.